Biotoxtech Co., Ltd. (KOSDAQ:086040)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,275.00
-30.00 (-1.30%)
At close: Sep 18, 2026

Biotoxtech Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
52,47647,01741,34132,63137,29232,717
Revenue Growth
20.88%13.73%26.69%-12.50%13.98%23.79%
Gross Profit
7,3855,8022,4991,86212,42910,509
Operating Income
-4,623-5,908-8,619-8,676800.054,632
Net Income
-3,9951,163-6,427-4,8782,7257,114
Earnings Per Share
-258.6974.43-405.00-316.14185.86444.28
EPS Growth
-----58.17%148.20%

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
29,25528,13232,38441,03830,77128,151
Total Debt
68,35962,50063,04961,59149,14027,049
Net Cash (Debt)
-39,104-34,367-30,665-20,553-18,3691,102
Net Cash Growth
------71.82%
Net Cash Per Share
-2532.09-2199.82-1932.30-1332.10-1255.0371.58

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
5,5406,636-7,120-16,238-1,3094,346
Capital Expenditures
-3,640-2,121-1,977-4,452-30,676-7,619
Free Cash Flow
1,9014,515-9,097-20,691-31,985-3,273
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
14.07%12.34%6.04%5.71%33.33%32.12%
Operating Margin
-8.81%-12.57%-20.85%-26.59%2.15%14.16%
Pretax Margin
-11.24%-0.74%-21.34%-36.26%-1.73%19.82%
Profit Margin
-7.61%2.47%-15.55%-14.95%7.31%21.74%
FCF Margin
3.62%9.60%-22.00%-63.41%-85.77%-10.00%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-38.06--43.7216.50
Forward PE
-25.3025.3025.3025.3025.30
P/FCF Ratio
18.829.80----
PS Ratio
0.680.941.273.013.203.59